Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 1, 2013, Pages 42-49

  Capranzano, Piera ^a   Ferreiro, Jose Luis ^a   Ueno, Masafumi ^a   Capodanno, Davide ^a   Dharmashankar, Kodlipet ^a   Darlington, Andrew ^a   Desai, Bhaloo ^a   Tello Montoliu, Antonio ^a   Rollini, Fabiana ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

cilostazol; clopidogrel responsiveness; diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; PLACEBO; PURINERGIC P2Y12 RECEPTOR; THROMBIN;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PLATELET REACTIVITY; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84871719026     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24416     Document Type: Article

References (34)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
2. Ferreiro JL, Angiolillo DJ,. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
3. Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
4. Angiolillo DJ, Ueno M,. Optimizing platelet inhibition in clopidogrel poor metabolizers therapeutic options and practical considerations. JACC Cardiovasc Interv 2011; 4: 411-414.
5. Goto S,. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6: 3-11.
6. Douglas JS Jr,. Pharmacologic approaches to restenosis prevention. Am J Cardiol 2007; 100: 10K-6K.
7. Lee BK, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy with aspirin, clopidogrel and cilostazol on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007; 100: 610-614.
8. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-2211.
9. Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011; 106: 253-262.
10. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial. J Am Coll Cardiol 2011; 57: 280-289.
11. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
12. Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-391.
13. Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomised controlled trials. EuroIntervention 2009; 5: 384-393.
14. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
15. Lee SW, Park SW, Kim YH, et al. DECLARE-Long Study Investigators. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007; 100: 1103-1108.
16. Chen KY, Rha SW, Li YJ, et al. Korea Acute Myocardial Infarction Registry Investigators. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
17. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181-1187.
18. Ahn Y, Jeong MH, Jeong JW, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72: 35-39.
19. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J 2009; 157: 733-739.
20. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837.
21. Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291.
22. Fox SC, Behan MW, Heptinstall S,. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35: 39-46.
23. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
24. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
25. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
26. Mehta SR, Tanguay JF, Eikelboom JW, et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 2010; 376: 1233-1243.
27. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
28. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators, Freij A, Thorsén M,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
29. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S,. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114: 774-782.
30. Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: Implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019-2027.
31. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010; 121: 43-51.
32. Ferreiro JL, Sibbing D, Angiolillo DJ,. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103: 1128-1135.
33. Ferreiro JL, Ueno M, Desai B, et al. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev Esp Cardiol. 2012; 65: 105-106.
34. Ferreiro JL, Angiolillo DJ,. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123: 798-813.